Potential drug-drug interactions analysis in Polish pediatric hemato-oncologic unit, including acute lymphoblastic leukemia patients.

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Pharmacological Reports Pub Date : 2025-04-01 DOI:10.1007/s43440-025-00719-4

Arkadiusz Adamiszak, Julia Drobińska, Izabela Niewiadomska-Wojnałowicz, Katarzyna Derwich, Edmund Grześkowiak, Agnieszka Bienert

{"title":"Potential drug-drug interactions analysis in Polish pediatric hemato-oncologic unit, including acute lymphoblastic leukemia patients.","authors":"Arkadiusz Adamiszak, Julia Drobińska, Izabela Niewiadomska-Wojnałowicz, Katarzyna Derwich, Edmund Grześkowiak, Agnieszka Bienert","doi":"10.1007/s43440-025-00719-4","DOIUrl":null,"url":null,"abstract":"Background: The lack of information on drug-drug interactions in the pediatric population significantly complicates making effective therapeutic decisions. Our study aimed to analyze the rate and risk factors as well as present potential drug-drug interactions (pDDIs) specifically for pediatric patients from the pediatric hemato-oncologic unit, including acute lymphoblastic leukemia (ALL) patients.Methods: We conducted a six-month prospective study in which clinical pharmacists examined medical records once a week to look for pDDIs using the Lexicomp® Drug Interactions Checker. Spearman's rank coefficient, logistic regression, and the U-Mann-Whitney test were used to identify correlations, analyze risk factors for pDDIs, and compare ALL patients with non-ALL patients, respectively. Recommendations were provided for the D and X pDDIs categories.Results: We identified 507 pDDIs in 119 screened patients, 388 of which were clinically relevant. Nearly 68% of the patients were exposed to at least one significant interaction. The number of pDDIs was positively correlated with the number of medications (rs=0.75, p < 0.001), off-label used drugs (rs=0.42, p < 0.001), comorbidities (rs=0.21, p = 0.019), and hospitalization length (rs=0.48, p < 0.001). The multivariate analysis revealed that at least 7 administered medications (OR = 8.63; 95% CI = 2.92-25.47) and 13 days in the hospital (OR = 3.47; 95% CI = 1.31-9.19) were risk factors for pDDIs. Furthermore, patients treated for ALL represent an at-risk group with a statistically higher number of drugs taken and pDDIs identified.Conclusions: Limited data on drug-drug interactions in the pediatric population emphasizes the need for close collaboration between clinical pharmacists and clinicians to improve the safety and effectiveness of pharmacotherapy.","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43440-025-00719-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The lack of information on drug-drug interactions in the pediatric population significantly complicates making effective therapeutic decisions. Our study aimed to analyze the rate and risk factors as well as present potential drug-drug interactions (pDDIs) specifically for pediatric patients from the pediatric hemato-oncologic unit, including acute lymphoblastic leukemia (ALL) patients.

Methods: We conducted a six-month prospective study in which clinical pharmacists examined medical records once a week to look for pDDIs using the Lexicomp^® Drug Interactions Checker. Spearman's rank coefficient, logistic regression, and the U-Mann-Whitney test were used to identify correlations, analyze risk factors for pDDIs, and compare ALL patients with non-ALL patients, respectively. Recommendations were provided for the D and X pDDIs categories.

Results: We identified 507 pDDIs in 119 screened patients, 388 of which were clinically relevant. Nearly 68% of the patients were exposed to at least one significant interaction. The number of pDDIs was positively correlated with the number of medications (r_s=0.75, p < 0.001), off-label used drugs (r_s=0.42, p < 0.001), comorbidities (r_s=0.21, p = 0.019), and hospitalization length (r_s=0.48, p < 0.001). The multivariate analysis revealed that at least 7 administered medications (OR = 8.63; 95% CI = 2.92-25.47) and 13 days in the hospital (OR = 3.47; 95% CI = 1.31-9.19) were risk factors for pDDIs. Furthermore, patients treated for ALL represent an at-risk group with a statistically higher number of drugs taken and pDDIs identified.

Conclusions: Limited data on drug-drug interactions in the pediatric population emphasizes the need for close collaboration between clinical pharmacists and clinicians to improve the safety and effectiveness of pharmacotherapy.

查看原文本刊更多论文

波兰儿科血液肿瘤科包括急性淋巴细胞白血病患者的潜在药物相互作用分析。

背景：在儿科人群中缺乏药物相互作用的信息，这使得做出有效的治疗决策变得非常复杂。我们的研究旨在分析儿科血液肿瘤科儿科患者（包括急性淋巴细胞白血病（ALL）患者）的发生率和危险因素，以及目前潜在的药物-药物相互作用（pddi）。方法：我们进行了一项为期六个月的前瞻性研究，其中临床药师每周检查一次医疗记录，使用Lexicomp®药物相互作用检查器寻找pddi。采用Spearman等级系数、logistic回归和U-Mann-Whitney检验来确定相关性，分析pddi的危险因素，并分别比较ALL患者和非ALL患者。对D类和X类发展规划指标提出了建议。结果：我们在119例筛查患者中发现507例pddi，其中388例与临床相关。近68%的患者至少接触过一种显著的相互作用。pddi次数与用药次数（rs=0.75, p =0.42, p =0.21, p = 0.019）和住院时间（rs=0.48, p）呈正相关（rs=0.48, p）。结论：儿科人群中药物-药物相互作用的有限数据强调临床药师和临床医生需要密切合作，以提高药物治疗的安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacological Reports 医学-药学

CiteScore

8.40

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Pharmacological Reports publishes articles concerning all aspects of pharmacology, dealing with the action of drugs at a cellular and molecular level, and papers on the relationship between molecular structure and biological activity as well as reports on compounds with well-defined chemical structures. Pharmacological Reports is an open forum to disseminate recent developments in: pharmacology, behavioural brain research, evidence-based complementary biochemical pharmacology, medicinal chemistry and biochemistry, drug discovery, neuro-psychopharmacology and biological psychiatry, neuroscience and neuropharmacology, cellular and molecular neuroscience, molecular biology, cell biology, toxicology. Studies of plant extracts are not suitable for Pharmacological Reports.